`To:
`Cc:
`
`Subject:
`Date:
`
`Pepe, Christopher
`Trials@uspto.gov
`Holland, Elizabeth J.; James, William G.; Cipriano, Linnea P; Grammel, Molly; Desai, Anish; Weiswasser,
`Elizabeth; Regeneron-IPR-Service; DG-NovartisPFS
`IPR2021-00816 - Request for Authorization
`Friday, August 6, 2021 1:31:17 PM
`
`Docket No.: IPR2021-00816
`Petitioner: Regeneron Pharmaceuticals, Inc.
`Patent Owner: Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corp.
`
`Your Honors,
`
`We represent Petitioner in IPR2021-00816. Petitioner respectfully requests a teleconference with
`the Board to seek authorization to submit a 10-page reply to Patent Owner’s Preliminary Response.
`Petitioner’s reply would address the following issues raised in the Preliminary Response:
`
`1. Patent Owner’s assertion that Petitioner could have raised Patent Owner’s termination of the
`ITC Investigation in a request for rehearing of IPR2020-01317;
`2. Patent Owner’s assertion that discovery taken in the ITC Investigation is relevant under
`General Plastic;
`3. Patent Owner’s assertions concerning the status of the NDNY action as it relates to Patent
`Owner’s Fintiv argument.
`
`
`The parties have conferred, and Patent Owner opposes Petitioner’s request. The parties are
`available for a teleconference with the Board between 3-5 pm eastern on either Tuesday (8/10) or
`Wednesday (8/11) next week.
`
`Respectfully submitted,
`
`Christopher Pepe
`Back-up Counsel for Petitioner
`
`
`
`Christopher Pepe
`
`Weil, Gotshal & Manges LLP
`2001 M Street NW, Suite 600
`Washington, DC 20036
`christopher.pepe@weil.com
`+1 202 682 7153 Direct
`+1 202 857 0940 Fax
`
`The information contained in this email message is intended only for use of the individual or entity named
`
`Novartis Exhibit 2095.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`above. If the reader of this message is not the intended recipient, or the employee or agent responsible to
`deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying
`of this communication is strictly prohibited. If you have received this communication in error, please
`immediately notify us by email, postmaster@weil.com, and destroy the original message. Thank you.
`
`Novartis Exhibit 2095.002
`Regeneron v. Novartis, IPR2021-00816
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
